Alnylam Pharmaceuticals (ALNY) reported first-quarter 2025 adjusted loss of 1 cent per share, narrower than the Zacks Consensus Estimate of a loss of 56 cents. The company had incurred a loss of 16 cents per share in the year-ago quarter. The adjusted figure excluded items like stock-based compensation expenses and unrealized loss on marketable equity securities.Alnylam recorded total revenues of $594.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $588.2 million. In the year-ago q ...

Alnylam Pharmaceuticals (ALNY) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Christine Lindenboom - Chief Corporate Communications OfficerYvonne Greenstreet - Chief Executive OfficerTolga Tanguler - Executive VP & Chief Commercial OfficerPushkal Garg - Chief Medical Officer and Executive VP of Development & Medical AffairsJeff Poulton - Chief Financial OfficerGena Wang - MD - Biotech Equity ResearchTeraesa Vitelli - Equity Research AssociateGary Nachman - Managing Director - Equity Res ...

Alnylam Pharmaceuticals (ALNY) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Q1 twenty twenty five Earnings Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 05/01/2025. I would now like to turn the conference over to Alnylam. Please go ahead. Speaker1 Good morning. I'm Christine Lindenbo ...